Maduck Sean sold $419K of CORT
Maduck Sean (See Remarks) sold 3,664 shares of CORCEPT THERAPEUTICS INC (CORT) at $114.49 ($0.42M total) on 2026-08-14 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new fact is the size, price, and timing of the officer’s open-market sale under a 10b5-1 plan; it does not include guidance, trial results, regulatory actions, or deal terms.
Market read
Traders may note insider selling, but the 10b5-1 structure and lack of accompanying fundamentals make this more of a sentiment datapoint than a catalyst.
What to watch
The filing does not indicate whether the sale was tax-related, diversification-related, or part of a scheduled liquidity program; without additional context, signal quality is low.
Background
The article is a SEC Form 4 insider transaction report for Corcept Therapeutics, filed on 2026-08-18, covering a sale executed 2026-08-14.
Ticker impact
Corcept Therapeutics disclosed an officer open-market sale of 3,664 shares at $114.49 on 2026-08-14 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely short-lived unless accompanied by other news.
Form 4 details a pre-arranged 10b5-1 sale and provides no new company-specific information beyond the transaction itself.
Market effects
Minimal; insider-sale Form 4s typically do not reset sector expectations for pharma/biotech.
None indicated.
None indicated.
Counterpoint
10b5-1 plans can lead to regular selling regardless of outlook, so the disclosure may be misread as bearish.
Key entities
- issuerCorcept Therapeutics Inc
Subject of the Form 4 insider transaction disclosure (ticker CORT).
- insiderMaduck Sean
Officer who sold 3,664 shares at $114.49 under a pre-arranged 10b5-1 plan.
